Immune responses to mRNA-based vaccines given as a third COVID-19 vaccine dose in people living with HIV — a literature review
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Immune responses to mRNA-based vaccines given as a third COVID-19 vaccine dose in people living with HIV — a literature review. / Knudsen, Maria Lodberg; Nielsen, Susanne Dam; Heftdal, Line Dam.
I: APMIS, Bind 132, Nr. 4, 2024, s. 236-244.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Immune responses to mRNA-based vaccines given as a third COVID-19 vaccine dose in people living with HIV — a literature review
AU - Knudsen, Maria Lodberg
AU - Nielsen, Susanne Dam
AU - Heftdal, Line Dam
N1 - Publisher Copyright: © 2024 The Authors. APMIS published by John Wiley & Sons Ltd on behalf of Scandinavian Societies for Pathology, Medical Microbiology and Immunology.
PY - 2024
Y1 - 2024
N2 - People living with HIV (PLWH) were not included in the first efficacy studies of mRNA vaccines against SARS-CoV-2. In this literature review, we investigate evidence of humoral and cellular immunity after a third dose of an mRNA vaccine in PLWH. We performed a literature search in PubMed, Embase, Web of Science and SCOPUS published between 1 January 2020 and 31 December 2022. Selection criteria were studies on immunological responses in PLWH, who were given an mRNA-based vaccine as a third vaccine dose against SARS-CoV-2. Eight articles complied with our selection criteria. All studies found a strong humoral response after the third dose. Five studies investigated cellular immunity and found an increased cellular response after the third vaccine dose in PLWH. No difference in humoral response was observed between PLWH and controls after three doses. However, some of the studies suggested a weaker cellular response among PLWH than in controls, which was associated with lower nadir or current CD4+ T-cell counts. In conclusion, we found evidence of strong humoral immunity in PLWH after receiving an mRNA-based COVID-19 vaccine as a third dose, while the cellular immunity may be impaired compared to controls.
AB - People living with HIV (PLWH) were not included in the first efficacy studies of mRNA vaccines against SARS-CoV-2. In this literature review, we investigate evidence of humoral and cellular immunity after a third dose of an mRNA vaccine in PLWH. We performed a literature search in PubMed, Embase, Web of Science and SCOPUS published between 1 January 2020 and 31 December 2022. Selection criteria were studies on immunological responses in PLWH, who were given an mRNA-based vaccine as a third vaccine dose against SARS-CoV-2. Eight articles complied with our selection criteria. All studies found a strong humoral response after the third dose. Five studies investigated cellular immunity and found an increased cellular response after the third vaccine dose in PLWH. No difference in humoral response was observed between PLWH and controls after three doses. However, some of the studies suggested a weaker cellular response among PLWH than in controls, which was associated with lower nadir or current CD4+ T-cell counts. In conclusion, we found evidence of strong humoral immunity in PLWH after receiving an mRNA-based COVID-19 vaccine as a third dose, while the cellular immunity may be impaired compared to controls.
KW - booster
KW - HIV
KW - Immune response
KW - mRNA vaccines
KW - SARS-CoV-2
U2 - 10.1111/apm.13379
DO - 10.1111/apm.13379
M3 - Review
C2 - 38275143
AN - SCOPUS:85183164404
VL - 132
SP - 236
EP - 244
JO - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica
JF - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica
SN - 0903-4641
IS - 4
ER -
ID: 384656998